ZA201502979B - A porous silica material for use as a pharmaceutical or dietary active ingredient - Google Patents

A porous silica material for use as a pharmaceutical or dietary active ingredient

Info

Publication number
ZA201502979B
ZA201502979B ZA2015/02979A ZA201502979A ZA201502979B ZA 201502979 B ZA201502979 B ZA 201502979B ZA 2015/02979 A ZA2015/02979 A ZA 2015/02979A ZA 201502979 A ZA201502979 A ZA 201502979A ZA 201502979 B ZA201502979 B ZA 201502979B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical
active ingredient
porous silica
silica material
range
Prior art date
Application number
ZA2015/02979A
Other languages
English (en)
Inventor
Robert Csikasz
Tore Bengtsson
Natalia Kupferschmidt
Alfonso E Garcia-Bennett
Original Assignee
Sigrid Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigrid Therapeutics Ab filed Critical Sigrid Therapeutics Ab
Publication of ZA201502979B publication Critical patent/ZA201502979B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/015Inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00Silicon; Compounds thereof
    • C01B33/113Silicon oxides; Hydrates thereof
    • C01B33/12Silica; Hydrates thereof, e.g. lepidoic silicic acid
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00Physical properties of inorganic compounds
    • C01P2006/12Surface area
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00Physical properties of inorganic compounds
    • C01P2006/14Pore volume
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00Physical properties of inorganic compounds
    • C01P2006/16Pore diameter
    • C01P2006/17Pore diameter distribution
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Silicon Compounds (AREA)
ZA2015/02979A 2012-11-06 2015-04-30 A porous silica material for use as a pharmaceutical or dietary active ingredient ZA201502979B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723019P 2012-11-06 2012-11-06
PCT/EP2013/073200 WO2014072363A1 (en) 2012-11-06 2013-11-06 A porous silica material for use as a pharmaceutical or dietary active ingredient

Publications (1)

Publication Number Publication Date
ZA201502979B true ZA201502979B (en) 2024-09-25

Family

ID=49639855

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/02979A ZA201502979B (en) 2012-11-06 2015-04-30 A porous silica material for use as a pharmaceutical or dietary active ingredient

Country Status (20)

Country Link
US (2) US10695294B2 (enExample)
EP (2) EP3892285A3 (enExample)
JP (2) JP6421124B2 (enExample)
CN (2) CN105188720A (enExample)
AU (1) AU2013343565B2 (enExample)
BR (1) BR112015010118A2 (enExample)
CA (3) CA3024640A1 (enExample)
CY (1) CY1124471T1 (enExample)
DK (1) DK2916852T3 (enExample)
ES (1) ES2878017T3 (enExample)
HR (1) HRP20211036T1 (enExample)
HU (1) HUE055017T2 (enExample)
IL (1) IL238538B (enExample)
LT (1) LT2916852T (enExample)
PH (1) PH12015501010B1 (enExample)
PL (1) PL2916852T3 (enExample)
PT (1) PT2916852T (enExample)
SI (1) SI2916852T1 (enExample)
WO (1) WO2014072363A1 (enExample)
ZA (1) ZA201502979B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013343565B2 (en) 2012-11-06 2018-07-26 Sigrid Therapeutics Ab A porous silica material for use as a pharmaceutical or dietary active ingredient
TWI614017B (zh) 2012-12-21 2018-02-11 財團法人國家衛生研究院 包含中孔洞矽奈米粒子之組成物的用途
EP3651789A4 (en) * 2017-07-13 2021-05-26 Carnegie Mellon University METHOD OF INCREASING EPITHELIAL PERMEABILITY USING NANOPARTICLES
EA202091351A1 (ru) * 2017-12-13 2020-09-15 Л.И.Ко.Райс С.Р.Л. Комплекс лактоферрина и диоксида кремния, способ получения и композиции для гигиены полости рта
GB201803363D0 (en) 2018-03-01 2018-04-18 Sigrid Therapeutics Ab New materials and uses thereof
WO2020212418A1 (en) * 2019-04-15 2020-10-22 Nanologica Ab Empty porous particles for use in treatment, prevention and/or postponement of degeneration of neurodegenerative diseases, neurons and glia.
CN110314151B (zh) * 2019-08-02 2020-06-02 深圳国佳产业基金管理有限公司 医用介孔二氧化硅材料及其应用
CN114729263A (zh) * 2019-09-30 2022-07-08 零点火技术股份有限公司 隔热阻燃材料及其制造方法
JP7578945B2 (ja) * 2020-10-27 2024-11-07 信越化学工業株式会社 イミダゾールシラン処理シリカからなる胆汁酸吸着剤
CN114195885B (zh) * 2022-01-12 2024-04-26 杭州隆基生物技术有限公司 一种单克隆抗体组合物提纯方法
CN118871077A (zh) 2022-02-04 2024-10-29 西格丽德治疗公司 包含多孔二氧化硅颗粒的口腔护理组合物
JP2025119063A (ja) 2022-04-28 2025-08-14 日本たばこ産業株式会社 無機多孔質材料を含む口腔用組成物
GB202212240D0 (en) 2022-08-23 2022-10-05 Sigrid Therapeutics Ab New formulations and medical uses thereof
GB202212239D0 (en) 2022-08-23 2022-10-05 Sigrid Therapeutics Ab New dietary supplements
CN116747321B (zh) * 2023-06-14 2025-09-05 厦门君德医药科技有限公司 一种接枝改性的介孔二氧化硅及其制备方法和应用
GB202312179D0 (en) 2023-08-09 2023-09-20 Sigrid Therapeutics Ab New compositions and uses
GB202312176D0 (en) 2023-08-09 2023-09-20 Sigrid Therapeutics Ab New uses and methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185088A (en) 1977-02-17 1980-01-22 Merck & Co., Inc. Non-adhesive ionene quaternary polymer compositions useful as bile acid sequestrants
US4180566A (en) * 1978-05-15 1979-12-25 W. R. Grace & Co. Silica gel method of reducing blood lipid concentration
US4824672A (en) * 1986-06-06 1989-04-25 Hauser-Kuhrts, Inc. Method and composition for reducing serum cholesterol
US5401466A (en) * 1993-06-01 1995-03-28 Miles Inc. Device for the direct measurement of low density lipoprotein cholesterol
EP0778027A3 (de) 1995-12-04 1998-04-01 Helmut Univ.-Prof. Dr. Wachter Verwendung von Kieselerde zur Herstellung von Arzneimitteln
EP0911078A1 (en) * 1997-10-20 1999-04-28 Hitachi Metals, Ltd. Photocatalyst-supporting body and photocatalytic apparatus
DK1093370T3 (da) * 1998-06-30 2006-05-22 Takeda Pharmaceutical Farmaceutisk præparat til behandling af diabetes
WO2001012221A1 (en) * 1999-08-16 2001-02-22 Henceforth Hibernia, Inc. Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them
RU2241462C2 (ru) 2000-07-28 2004-12-10 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция
US7074440B2 (en) * 2002-05-01 2006-07-11 Rulin Xiu Compositions and methods for body weight loss
JP2004345895A (ja) * 2003-05-21 2004-12-09 Ajinomoto Co Inc メソポーラスシリカ及びその製造方法
JP2005289853A (ja) * 2004-03-31 2005-10-20 Ajinomoto Co Inc 経口リン酸吸着剤
GB0515353D0 (en) 2005-07-27 2005-08-31 Psimedica Ltd Food
KR100857411B1 (ko) 2006-07-21 2008-09-08 한올제약주식회사 리파아제 저해제의 경구 투여용 방출조절 약학 제제 및이의 제조 방법
CN101939258B (zh) 2008-02-11 2014-05-14 纳诺洛吉卡股份公司 中孔材料的制造方法、这样生产的材料以及中孔材料的用途
TW200936130A (en) * 2008-02-26 2009-09-01 Lundbeck & Co As H Uses of indane compounds
EP2271358B1 (en) * 2008-03-25 2018-11-21 Amarantus Therapeutics, Inc. use of mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease
JP2010065023A (ja) * 2008-08-14 2010-03-25 Lion Corp 脂溶性ビタミンおよび/または脂溶性色素含有粉体
EP2349336B1 (en) * 2008-10-28 2017-11-22 Agency For Science, Technology And Research Mesoporous material excipients for poorly aqueous soluble ingredients
DE102009026686A1 (de) * 2009-06-03 2010-12-23 Airbus France Anordnung zum Blitzschutz einer elektronischen Einheit
EP2547733A1 (en) 2010-03-17 2013-01-23 Nanologica AB Enhanced folic acid fluorescent material, multifluorescent porous compositions of matter and potential applications thereof
ES2768229T3 (es) * 2010-07-06 2020-06-22 Nanologica Ab Método mejorado para diferenciación de células madre in vivo mediante la administración de morfógenos con sílice mesoporosa y principios activos farmacéuticos correspondientes
GB201212866D0 (en) 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
AU2013343565B2 (en) 2012-11-06 2018-07-26 Sigrid Therapeutics Ab A porous silica material for use as a pharmaceutical or dietary active ingredient
EP2919903B1 (en) 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions containing a biologically active material and a non-ordered inorganic oxide
TWI614017B (zh) 2012-12-21 2018-02-11 財團法人國家衛生研究院 包含中孔洞矽奈米粒子之組成物的用途

Also Published As

Publication number Publication date
CA3024640A1 (en) 2014-05-15
PT2916852T (pt) 2021-06-15
JP2015536939A (ja) 2015-12-24
US10695294B2 (en) 2020-06-30
US12121612B2 (en) 2024-10-22
HRP20211036T1 (hr) 2021-10-01
PH12015501010A1 (en) 2015-07-27
CA3024460A1 (fr) 2018-11-15
CN113069467A (zh) 2021-07-06
CN105188720A (zh) 2015-12-23
PL2916852T3 (pl) 2021-11-02
PH12015501010B1 (en) 2023-10-20
EP3892285A3 (en) 2021-11-17
JP6421124B2 (ja) 2018-11-07
HUE055017T2 (hu) 2021-10-28
LT2916852T (lt) 2021-06-25
CA2890171A1 (en) 2014-05-15
IL238538A0 (en) 2015-06-30
EP2916852A1 (en) 2015-09-16
US20150258028A1 (en) 2015-09-17
BR112015010118A2 (pt) 2017-07-11
AU2013343565A1 (en) 2015-05-21
IL238538B (en) 2019-06-30
ES2878017T3 (es) 2021-11-18
US20200390703A1 (en) 2020-12-17
EP3892285A2 (en) 2021-10-13
EP2916852B1 (en) 2021-04-14
CA2890171C (en) 2019-01-22
AU2013343565B2 (en) 2018-07-26
CY1124471T1 (el) 2022-07-22
JP2019023222A (ja) 2019-02-14
DK2916852T3 (en) 2021-05-10
SI2916852T1 (sl) 2021-08-31
WO2014072363A1 (en) 2014-05-15
JP6752858B2 (ja) 2020-09-09

Similar Documents

Publication Publication Date Title
ZA201502979B (en) A porous silica material for use as a pharmaceutical or dietary active ingredient
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
GB201204696D0 (en) Therapy
MX348823B (es) Formulaciones estables de linaclotida.
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
SG10201804817TA (en) Delayed release compositions of linaclotide
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
PH12014502496B1 (en) Bicyclically substituted uracils and the use thereof
GB2492265A (en) Hydraulic lime composition
WO2013128402A3 (en) Porous inorganic body
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2011138197A3 (en) Novel low concentration meloxicam tablets
MX2014012164A (es) Composiciones a base de probioticos y un complejo de polen de abejas/arcilla, su preparacion y sus usos en nutricion y en terapeutica.
PH12015500610A1 (en) Oral care composition
PH12019500690A1 (en) Oral care composition
IN2014DN07379A (enExample)
EP2983684B8 (en) Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations
MX2013013079A (es) Composiciones que comprenden un agente antibacterial y tazobactam.
WO2015024577A3 (fr) Composition a base de safranal
WO2015044434A3 (de) FLUOR-9-METHYL-ß-CARBOLINE
EP2885345B8 (en) Azeotropic and azeotrope-like compositions of 2,3,3,4,4,4-hexafluoro-1-butene and 1,1,1,2,3,3-hexafluoropropane and uses thereof
WO2013038200A3 (en) Neurodevelopmental disorders
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
IL235095A0 (en) Intrauterine application of 18-methyl-15 in cell, 16 in cell-methylene-19-nor-20-spirox-4-en-3-one systems, intrauterine systems containing 18-methyl-15 in cell, 16 in cell-methylene- 19-nor-20-spirox-4-en-3-one and their use in contraception and gynecological treatment